Target intelligence / Profile preview

Ribosomal protein lateral stalk subunit P2 (RPLP2)

Target
RPLP2
Molecular classification
Other, Ribosomal protein, Structural ribosome subunit
01

Overview

Ribosomal protein lateral stalk subunit P2 (RPLP2) is an acidic phosphoprotein component of the eukaryotic large (60S) ribosomal subunit, integral to the ribosomal stalk structure. It interacts with P0 and P1 proteins to form a pentameric complex facilitating the recruitment and positioning of translation factors at the ribosome’s GTPase center, which is essential for the elongation phase of protein synthesis. RPLP2 is structurally a functional equivalent to the E. coli L7/L12 protein and belongs to the L12P family. It is implicated in modulation of translational activity and cell proliferation rates. While not typically a direct drug target, the protein’s conserved C-terminal region mediates interactions with ribosome-inactivating proteins such as ricin and trichosanthin, which exploit this interaction to inhibit protein synthesis. RPLP2 is also recognized as an antigen in renal carcinoma, though its broader role in human disease is primarily linked to its function in the ribosome

Other names
Large ribosomal subunit protein P2D11S2243ERPP2LP260S acidic ribosomal protein P2acidic ribosomal phosphoprotein P2renal carcinoma antigen NY-REN-44ribosomal protein, large, P2
02

Mechanism of action

Not directly targeted by drugs; mechanism for toxins/RIPs involves binding to the conserved C-terminal domain and inactivating the ribosome by preventing elongation factor binding

03

Biological functions

Protein synthesisPeptide chain elongationStructural constituent of ribosomeModulation of translationRegulation of cell proliferation
04

Disease associations

Cancer (implicated in gastric cancer and as a renal carcinoma antigen)possibly involved in autosomal recessive spinocerebellar ataxia 3
05

Safety considerations

None known for direct targetinginhibiting ribosomal proteins may impair general protein synthesis and cell viability
06

Interacting drugs

None known
07

Biomarkers

Renal carcinoma antigen NY-REN-44 (recognized in renal carcinoma)

Beyond the preview

Go deeper on Ribosomal protein lateral stalk subunit P2 (RPLP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein lateral stalk subunit P2 (RPLP2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call